Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters

References

• Aliabadi AZ, Mahr S, Dunkler D, Grömmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO. (2008). Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 86:1771–1776.
   PubMed Web of Science ®Google Scholar
• Annaert P, Ye ZW, Stieger B, Augustijns P. (2010). Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163–176.
   PubMed Web of Science ®Google Scholar
• Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C, Zoellner U, Shand N, Calvo F, Raymond E. (2009). Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 100:315–321.
   PubMed Web of Science ®Google Scholar
• Crowe A, Lemaire M. (1998). In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15:1666–1672.
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P; RAD B253 Study Group. (2003). Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349:847–858.
   PubMed Web of Science ®Google Scholar
• Fehrenbach T, Cui Y, Faulstich H, Keppler D. (2003). Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 368:415–420.
   PubMed Web of Science ®Google Scholar
• Franke RM, Scherkenbach LA, Sparreboom A. (2009). Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10:339–344.
   PubMed Web of Science ®Google Scholar
• Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Müllertz A, Mönkkönen J, O’Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL. (2008). Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 35:383–396.
   PubMed Web of Science ®Google Scholar
• Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693–705.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. (2002). Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 42:222–228.
   PubMed Web of Science ®Google Scholar
• Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, Fardel O. (2006). Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109–117.
   PubMed Web of Science ®Google Scholar
• Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. (2005). Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 5:2236–2243.
   PubMed Web of Science ®Google Scholar
• Mulders P. (2009). Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int 104:1585–1589.
   PubMed Web of Science ®Google Scholar
• Niemi M. (2007). Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802.
   PubMed Web of Science ®Google Scholar
• Oswald S, Nassif A, Modess C, Keiser M, Hanke U, Engel A, Lütjohann D, Weitschies W, Siegmund W. (2010). Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther 87:663–667.
   PubMed Web of Science ®Google Scholar
• Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, Marquet P. (2010). The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther 87:100–108.
   PubMed Web of Science ®Google Scholar
• Rothenburger M, Teerling E, Bruch C, Lehmkuhl H, Suwelack B, Bara C, Wichter T, Hinder F, Schmid C, Stypmann J. (2007). Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months’ follow-up. J Heart Lung Transplant 26:250–257.
   Google Scholar
• Ruiz JC, Sánchez A, Rengel M, Beneyto I, Plaza JJ, Zárraga S, Errasti P, Andrés A, Morales JM, Torregrosa JV, Alarcón A, Morey A, Romero R, Fernández A, Díaz JM, Cantarell C; EVERODATA Group. (2007). Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 39:2157–2159.
   PubMed Web of Science ®Google Scholar
• Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. (2006). Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 34:1423–1431.
   PubMed Web of Science ®Google Scholar
• Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753–761.
   PubMed Web of Science ®Google Scholar
• Sauvage FL, Gaulier JM, Lachâtre G, Marquet P. (2006). A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum. Ther Drug Monit 28:123–130.
   PubMedGoogle Scholar
• Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. (2003). Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616.
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sato H, Sugiyama Y. (2005). Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689–723.
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. (2004). Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167–177.
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. (2010). Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76.
   PubMed Web of Science ®Google Scholar